Form 4: Evolus CEO Moatazedi Awarded Significant Equity Grants

Evolus, Inc. CEO David Moatazedi received substantial grants of restricted stock units, performance stock units, and stock options, aligning his compensation with future company performance.

Summary

• David Moatazedi, President and CEO of Evolus, Inc., was granted 313,212 Restricted Stock Units (RSUs) on February 17, 2026.
• He also received 626,424 Performance Restricted Stock Units (PSUs) on February 17, 2026, which can vest up to 200% of the target number of shares based on financial metrics and relative total shareholder return over a three-year period ending December 31, 2028.
• Additionally, Moatazedi was granted stock options to purchase 457,541 shares of common stock at an exercise price of $4.39 per share, also on February 17, 2026.
• The RSUs and stock options will vest in four equal annual installments starting from February 17, 2026, contingent on continued service.
• Following these transactions, Moatazedi beneficially owns 667,600 shares of common stock, 626,424 PSUs, and 457,541 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a standard and generally positive development for corporate governance, as it aligns the CEO's incentives with long-term shareholder value. The performance-based component is a strong positive, though the grants also represent potential future dilution.

Positives

• Significant equity grants to the CEO align management's interests with long-term shareholder value creation.
• Performance-based stock units (PSUs) tie a substantial portion of compensation directly to the achievement of pre-established financial metrics and relative total shareholder return, incentivizing strong company performance.
• The vesting schedules for RSUs and stock options promote executive retention over a four-year period.

Negatives

• The grants represent potential future dilution for existing shareholders if all equity awards fully vest and are exercised.
• The value of these grants is dependent on future stock price performance and company achievement, introducing variability in executive compensation.

Risks

• Performance-based compensation risk: The actual number of shares received from PSUs is uncertain and depends on the company's ability to meet specific financial metrics and achieve favorable relative total shareholder return over the three-year performance period ending December 31, 2028.
• Service-based vesting risk: The vesting of RSUs and stock options is contingent on David Moatazedi's continued service to the company, meaning unvested awards would be forfeited upon certain terminations.
• Market price risk: The ultimate value realized from the stock options and vested equity awards is subject to the future market price of Evolus, Inc. common stock.

Future Outlook

The filing does not provide a general future outlook for the company, but the performance-based restricted stock units are tied to financial metrics and relative total shareholder return over a three-year period ending December 31, 2028, indicating management's focus on long-term value creation.

Management Comments

• No direct quotes or paraphrased statements from company management are included in this Form 4 filing, beyond the signature of the attorney-in-fact for David Moatazedi.

Industry Context

StockSavvy.ai notes that the granting of substantial equity awards, including RSUs, PSUs, and stock options, is a common practice in the biotechnology and specialty pharmaceutical industries for executive compensation. This structure aims to align the interests of top executives with those of shareholders by making a significant portion of their compensation dependent on the company's stock performance and strategic achievements. This approach is particularly prevalent in growth-oriented sectors where long-term value creation is a primary objective.

Comparison to Industry Standards

• StockSavvy.ai observes that the compensation structure for Evolus's CEO, involving a mix of time-based RSUs, performance-based PSUs, and stock options, is consistent with best practices in executive compensation within the pharmaceutical and biotech sectors.
• The inclusion of PSUs tied to both financial metrics and relative TSR is a robust approach, mirroring compensation designs seen at peers such as Galderma or Merz Aesthetics, which also operate in the aesthetics market.
• The exercise price of $4.39 for the stock options would typically be set at the market price on the grant date, which is standard practice.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for long-term value creation if performance targets are met, but also potential for future dilution from the vesting and exercise of equity awards.
• Employees: May signal stability in leadership and a commitment to long-term growth, potentially impacting morale and retention.
• Management: Provides significant long-term incentives and compensation tied to company performance and continued service.

Next Steps

• The RSUs and stock options will begin vesting in four equal annual installments on each anniversary of February 17, 2026.
• The performance of the PSUs will be evaluated against pre-established financial metrics and relative total shareholder return over a three-year period ending December 31, 2028, with vesting occurring after certification of performance results.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation grants, which are an expected part of a public company's governance and incentive structure. While the grants align management's interests with shareholders, they do not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals and market conditions, rather than this specific compensation disclosure.

Keywords

Evolus, EOLS, David Moatazedi, CEO compensation, equity grant, restricted stock units, performance stock units, stock options, insider transaction, executive compensation, corporate governance